Latest Biotech News

AdAlta Limited has announced a pro rata renounceable rights offer to raise approximately $1.29 million, aiming to fund its strategic pivot towards licensing CAR-T cell therapies through its subsidiary AdCella. The offer includes new shares and options, underpinned by key insiders and an underwriting agreement.

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.

Nyrada Inc. has cleared the Safety Review Committee’s scrutiny for its Phase I clinical trial, progressing to the third dosing cohort of its promising neuroprotective and cardioprotective drug candidate NYR-BI03.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

BluGlass Limited has achieved a world-record 1250mW single-mode GaN laser chip and strengthened its commercial pipeline with a $120,000 repeat order, positioning itself for rapid growth in photonics markets.

Hexima Limited reported a stable cash position of $1.55 million at quarter-end, with a modest $87,000 net cash outflow from operations. The biotech company continues to explore strategic opportunities while maintaining a strong funding runway.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.

Imagion Biosystems has progressed its MagSense HER2 breast cancer imaging agent towards a pivotal Investigational New Drug application with the FDA, backed by a solid funding runway exceeding 13 quarters.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Starpharma reports steady progress in its DEP® drug development programs, launches new marketing campaigns in key regions, and maintains a strong cash position of $17.2 million as it refines clinical strategies and partnerships.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

INOVIQ Limited reports significant progress in its exosome-based cancer diagnostics and therapeutics, including expanded customer adoption, advanced AI screening tests, and strategic partnerships with leading research centres.